Bezlotoxumab (Zinplava®)

Assessment Status Rapid Review complete
Drug Bezlotoxumab
Brand Zinplava®
Indication Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.
Assessment Process
Rapid review commissioned 11/05/2017
Rapid review completed 14/06/2017
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full pharmacoeconomic assessment commissioned by HSE 14/06/2017

The company do not plan to submit a HTA dossier to the NCPE therefore the cost effectiveness of the technology cannot be proven.